Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Benatar

Showing results (131-140 of 242) with videos related to

Pageof 25
Sort By:
The New England Journal of Medicine|April 9, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia GravisRichard J Nowak, Michael Benatar, Emma Ciafaloni, et al.
Annals of Clinical and Translational Neurology|December 8, 2023
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extensionRichard J Nowak, Ari Breiner, Vera Bril, et al.
AJNR. American Journal of Neuroradiology|September 18, 2025
Progressive and short-interval changes observed in the corticospinal tract and corpus callosum of ALS patients: A texture analysis studyPedram Parnianpour, Matthew Harrison, Michael Benatar, et al.
Muscle & Nerve|May 15, 2012
Recommendations for myasthenia gravis clinical trialsMichael Benatar, Donald B Sanders, Ted M Burns, et al.
RNA (New York, N.Y.)|June 17, 2026
A mutation in the nuclear speckle and splicing factor SRRM2 is associated with multisystem proteinopathy and causes dysregulation of synapse-associated genesQingyu Shi, Chloe Lauder, Jolie Marie Miller, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
Experimental Neurology|January 10, 2016
C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cellsRustam Esanov, Kinsley C Belle, Marka van Blitterswijk, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
Frontiers in Neurology|April 12, 2019
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral SclerosisPaul Lingor, Markus Weber, William Camu, et al.
Neurology|July 28, 2025
Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral SclerosisMichael Benatar, Xueya Cai, Michael P McDermott, et al.
Pageof 25

Showing results (131-140 of 242) with videos related to

Sort By:
Pageof 25
The New England Journal of Medicine|April 9, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia GravisRichard J Nowak, Michael Benatar, Emma Ciafaloni, et al.
Annals of Clinical and Translational Neurology|December 8, 2023
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extensionRichard J Nowak, Ari Breiner, Vera Bril, et al.
AJNR. American Journal of Neuroradiology|September 18, 2025
Progressive and short-interval changes observed in the corticospinal tract and corpus callosum of ALS patients: A texture analysis studyPedram Parnianpour, Matthew Harrison, Michael Benatar, et al.
Muscle & Nerve|May 15, 2012
Recommendations for myasthenia gravis clinical trialsMichael Benatar, Donald B Sanders, Ted M Burns, et al.
RNA (New York, N.Y.)|June 17, 2026
A mutation in the nuclear speckle and splicing factor SRRM2 is associated with multisystem proteinopathy and causes dysregulation of synapse-associated genesQingyu Shi, Chloe Lauder, Jolie Marie Miller, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
Experimental Neurology|January 10, 2016
C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cellsRustam Esanov, Kinsley C Belle, Marka van Blitterswijk, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
Frontiers in Neurology|April 12, 2019
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral SclerosisPaul Lingor, Markus Weber, William Camu, et al.
Neurology|July 28, 2025
Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral SclerosisMichael Benatar, Xueya Cai, Michael P McDermott, et al.
Pageof 25